{"ticker": {"uuid": "c6bed5d1-c819-4bf9-90cf-701a31428415", "symbol": "4892", "name": "Cyfuse Biomedical K.K.", "exchange": "JPX", "country": "JP", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Enterprise value to revenue forward of Cyfuse Biomedical K.K. \u2013 TSE:4892", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdEZOQUZYS1ZQMURzNmw4TGVKeVRmVU9zZm5VQTVhRklqRk9OMkdyZWNPanBxbEZLV200OVAtQnFzem1DUDJ4UnUtUnFLTG1uRTRtTXlhZG9SdU1UeXcxc3FnT0R5NksxUXc0UE4zaUZxMzg2dWV5Wk1GbHpGd3kzRktEemtVQ3E1NUdWWjJkQkRaR29aaGdWelVoeVVMTm1OLXU5aE5yR2E?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T10:27:51+00:00", "published_display": "10 Jul 2026 10:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHC and Cyfuse Develop Innovative Production Technology for the Commercialization of 3D Cell Products", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNRHdrT3VxeWhiQkVteEZDaldhZHZraHduR3doRUtCdkF3MnFhM3duV1JKendxeERrLUkzWEdLWGhWak5NM0dWSG84ak01R3hRRHhXZFVSUUhUbFotbjdMUGQzQW85cXNwdVVrQ3lwMXBwYVYxb0h5M3cwWVhXU05NcFJBTll3eVNGekJMX0dDQkZzeDBveG9qV25Za21NZ0JzTHlLZTlxX3NFSlRnZVB1aGxHRGhmZjNOOXYxdjRvcjFrZXh1bXRLZ1NBcVlTbTBZR0dqZGpZWWQwdFdXU1lDX00weXg5TV9lRTU4TDkxNA?oc=5", "source_name": "Business Wire", "published_at": "2025-03-19T07:00:00+00:00", "published_display": "19 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to revenue forward of Cyfuse Biomedical K.K. \u2013 TSE:4892", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdEZOQUZYS1ZQMURzNmw4TGVKeVRmVU9zZm5VQTVhRklqRk9OMkdyZWNPanBxbEZLV200OVAtQnFzem1DUDJ4UnUtUnFLTG1uRTRtTXlhZG9SdU1UeXcxc3FnT0R5NksxUXc0UE4zaUZxMzg2dWV5Wk1GbHpGd3kzRktEemtVQ3E1NUdWWjJkQkRaR29aaGdWelVoeVVMTm1OLXU5aE5yR2E?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T10:27:51+00:00", "published_display": "10 Jul 2026 10:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHC and Cyfuse Develop Innovative Production Technology for the Commercialization of 3D Cell Products", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxNRHdrT3VxeWhiQkVteEZDaldhZHZraHduR3doRUtCdkF3MnFhM3duV1JKendxeERrLUkzWEdLWGhWak5NM0dWSG84ak01R3hRRHhXZFVSUUhUbFotbjdMUGQzQW85cXNwdVVrQ3lwMXBwYVYxb0h5M3cwWVhXU05NcFJBTll3eVNGekJMX0dDQkZzeDBveG9qV25Za21NZ0JzTHlLZTlxX3NFSlRnZVB1aGxHRGhmZjNOOXYxdjRvcjFrZXh1bXRLZ1NBcVlTbTBZR0dqZGpZWWQwdFdXU1lDX00weXg5TV9lRTU4TDkxNA?oc=5", "source_name": "Business Wire", "published_at": "2025-03-19T07:00:00+00:00", "published_display": "19 Mar 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 63, "total_relevant": 2, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 2, "score": 50, "total": 2, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 58, "events": [{"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}, {"event": "general", "label": "Market update", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 552.0, "latest_week": "2026-07-10", "one_week_move": -0.7, "four_week_move": 2.8, "twelve_week_move": -12.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.187807, "market_dynamics_buy_signal": false, "relative_strength": -31.704796, "fair_value_gap": -21.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.6331, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.7% over one week, +2.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 40, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 1}, {"label": "Business Wire", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 2}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 1}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "58/100 classification confidence."}, {"label": "Company focus", "value": "2", "tone": "neutral", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.7% over one week, +2.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to revenue forward of Cyfuse Biomedical K.K. \u2013 TSE:4892"}], "updated_at": "2026-07-17T01:04:15.115669+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}